We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Global Insights on Implantable Cardioverter-Defibrillators in High-Risk Hypertrophic Cardiomyopathy: Efficacy and Outcomes

MedXY Editorial Team•Aug 29, 2026•Cardiology
sudden cardiac deathHypertrophic Cardiomyopathyimplantable cardioverter-defibrillator

Highlight

This large-scale, international study involving over 3300 patients with hypertrophic cardiomyopathy (HCM) demonstrates that implantable cardioverter-defibrillators (ICDs) effectively prevent sudden cardiac death by terminating life-threatening ventricular arrhythmias. Key findings include a 16% event rate of appropriate ICD therapies, low device failure rates, and high survival free from HCM-related mortality over two decades.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Unveiling a Cryptic MYBPC3 Variant Amplifying Missplicing in Hypertrophic CardiomyopathyA deep-intronic MYBPC3 variant magnifies natural mRNA missplicing events, causing hypertrophic cardiomyopathy and explaining previously genotype-negative cases through an ancient founder effect and novel splice regulation.Sep 18, 2026Physiological Left Atrial Staging as a Predictor of New-Onset Atrial Fibrillation in Hypertrophic CardiomyopathyA novel left atrial (LA) staging system, integrating hemodynamic load and contractile function, predicts new-onset atrial fibrillation risk in hypertrophic cardiomyopathy and may guide tailored AF surveillance.Sep 15, 2026Evolving Impact of Implantable Cardioverter-Defibrillators on Mortality Post-Myocardial Infarction: Insights from the PROFID StudyThe PROFID study reveals a declining mortality benefit from primary prevention implantable cardioverter-defibrillators in post-myocardial infarction patients with reduced ejection fraction over recent decades, highlighting changing clinicalAug 29, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Rigosertib: A Promising Therapeutic Agent for Reversing Hypertrophic Cardiomyopathy in Noonan Syndrome
Rigosertib demonstrates significant reversal of hypertrophic cardiomyopathy and other syndromic features in Noonan syndrome models, highlighting its potential as a targeted therapy for RASopathy-associated cardiac and developmental abnormal
Aug 19, 2026
AI-Enabled ECG as a New Surveillance Tool for Left Ventricular Dysfunction in Hypertrophic Cardiomyopathy on MavacamtenThis study explores the potential of an AI-powered ECG tool to monitor left ventricular systolic dysfunction in hypertrophic cardiomyopathy patients treated with mavacamten, offering a less burdensome alternative to frequent echocardiogramsAug 12, 2026
Silent Killers: Unveiling the Hidden Cardiac Pathologies Behind Sudden Cardiac DeathThis study reveals that two-thirds of community sudden cardiac deaths occur in individuals without diagnosed cardiac disease, with half harboring occult myocardial infarction or dilated cardiomyopathy, underscoring the need for improved detAug 18, 2026